Search clinical trials for: CpG 7909

Total 2531 results

University of Iowa
National Cancer Institute (NCI); Mayo Clinic; Pfizer

Completed

A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

Chronic Lymphocytic Leukemia

United States
Stanford University
National Institutes of Health (NIH)

Withdrawn

Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.

Mycosis Fungoides
Ronald Levy
American Society of Clinical Oncology; Lymphoma Research Foundation

Completed

CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas

Mycosis Fungoides | Non-Hodgkin Lymphoma

United States
Pfizer

Completed

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Carcinoma, Breast

United States
Pfizer

Completed

CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Carcinoma, Renal Cell
Ronald Levy
Pfizer

Completed

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Lymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell

United States
Pfizer

Completed

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Melanoma | Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Lymphoma, T-Cell

United States, Germany
Pfizer

Completed

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Lymphoma, T-Cell, Cutaneous
Ludwig Institute for Cancer Research

Completed

Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer

Prostate Cancer

Switzerland, Germany
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

Malaria

United States
Wakayama Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer

Esophageal Cancer

Japan
National Institute of Allergy and Infectious Diseases...

Terminated

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

Bacterial Sepsis

United States
University of Aarhus
Aarhus University Hospital

Completed

Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults (ITAP)

HIV Infections

Denmark
Ludwig Institute for Cancer Research

Terminated

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Malignant Melanoma

Belgium
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909

Malaria

United Kingdom
Mayo Clinic

Withdrawn

FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

Cardiac Disease
Pfizer

Completed

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Carcinoma, Metastatic Breast

United States
Ahmad Tarhini
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Intraocular Melanoma | Malignant Conjunctival Neoplasm | Melanoma (Skin)

United States
National Institute of Allergy and Infectious Diseases...

Completed

Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)

Healthy Volunteer | HV

United States
Ludwig Institute for Cancer Research

Completed

A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.

Cancer | Neoplasm

Germany
National Institute of Allergy and Infectious Diseases...
National Institute of Allergy and Infectious Diseases@@@Coley Pharmaceutical...

Completed

Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria

Malaria

Mali
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria

Malaria

United Kingdom
Pfizer

Completed

CPG 7909 Injection in Melanoma

Carcinoma, Melanoma
Ronald Levy
National Institutes of Health (NIH)

Completed

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Lymphoma, Mantle-Cell

United States
National Institute of Allergy and Infectious Diseases...

Completed

Malaria Vaccine for Children in Mali

Malaria | Malaria Infection

Mali
Sandoz

Completed

To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions

Healthy
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali

Malaria

United States, Mali
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant

Malaria

United States
Ludwig Institute for Cancer Research

Terminated

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Malignant Melanoma

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

Plasmodium Falciparum Malaria

United States
Bionos Biotech S.L.

Completed

Bioavailability of Different Collagen-based Treatments After Oral Intake

Healthy Volunteers

Spain
LMU Klinikum

Not yet recruiting

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)

Schizophrenia
University Hospital, Grenoble
Clinical Investigation Centre for Innovative Technology Network; University... and other collaborators

Completed

Computer-assisted Fetal Monitoring - Obstetrics (SURFAO-Obst)

ECG-PCG-CTG Acquisition on Pregnant Voluntary Subjects

France
Ahram Canadian University

Completed

Post-instrumentation Pain After Use of the Fanta and M3 Pro Gold Systems

Endodontic Treatment

Egypt
University of Maryland, Baltimore

Recruiting

Testing the Pain Clinical Practice Guideline

Pain | Dementia

United States
Brooke Army Medical Center
University of Utah

Recruiting

Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)

Knee Osteoarthritis

United States
Pfizer

Completed

CPG 7909 Injection in Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

United States, Canada, Germany
Chinese University of Hong Kong
Integrated Community Centers for Mental Wellness

Active, not recruiting

Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis (AIM_AT)

Psychotic Disorders | Early Psychosis

Hong Kong
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

Advanced Malignant Cancer

China
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Allergy

United Kingdom, New Zealand, Netherlands, Sweden
Regeneron Pharmaceuticals

Completed

Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Cat Allergy | Mild Asthma

France
Merck Sharp & Dohme LLC

Terminated

Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)

Chronic Hepatitis C Infection
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

Allergy

United States
Yungjin Pharm. Co., Ltd.

Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Korea, Republic of
University of Jena

Completed

Nutritional Evaluation of Canola Protein in Comparison With Soy Protein

Men

Germany
Assistance Publique - Hôpitaux de Paris

Completed

Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma

Glioblastoma

France
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin... and other conditions

United States
Flare Therapeutics Inc.

Recruiting

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Advanced Solid Tumors Cancer | Advanced Urothelial Carcinoma | Open Label | Oral Drug Administration

United States
SBI Biotech Co., Ltd.

Terminated

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Leukemia

United States
Mentor Worldwide, LLC

Completed

CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study)

Breast Augmentation | Breast Reconstruction | Breast Revision

United States

Search clinical trials for: CpG 7909

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations